M. Neubauer

发表

Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model

J. Frytak, Brigham Walker, Jad E Hayes, 2020, JAMA network open.

Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.

M. Neubauer, L. Asmar, T. Whitaker, 2005, Clinical lung cancer.

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

E. Winer, N. Robert, R. Carlson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr).

J. Berlin, J. Hecht, H. Burris, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX‐710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer

Bruce E. Johnson, T. Lynch, C. Langer, 2007, Cancer.

Expectations in the care of lung cancer.

N. Leighl, R. Lilenbaum, M. Neubauer, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

M. Galsky, D. V. Von Hoff, M. Fleming, 2012, Investigational New Drugs.

Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial

David A. Smith, C. Obasaju, M. Socinski, 2007 .

Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.

M. Neubauer, L. Asmar, J. Schwartz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023

C. Yiannoutsos, N. Hanna, R. Govindan, 2007 .

Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.

D. Garfield, M. Neubauer, L. Asmar, 2005, Lung cancer.

B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023

Cynthia S. Johnson, C. Yiannoutsos, N. Hanna, 2007 .

Three-Year Results of a Medicare Advantage Cancer Management Program.

J. R. Hoverman, Jad E Hayes, M. Neubauer, 2018, Journal of oncology practice.

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in 2 distinct databases.

D. Patt, R. Beveridge, T. Cartwright, 2011, The American journal of managed care.

Redefining Quality Measurement in Cancer Care.

R. Carlson, M. Smith, K. Adelson, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Hospice or Hospital: The Costs of Dying of Cancer in the Oncology Care Model

J. R. Hoverman, Jad E Hayes, M. Neubauer, 2020, Palliative medicine reports.

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

E. Dees, J. O’Shaughnessy, J. Blum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telemedicine in Community Cancer Care: How Technology Helps Patients With Cancer Navigate a Pandemic

D. Patt, M. Neubauer, L. Wilfong, 2021, JCO oncology practice.

Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI

David A. Smith, R. Sikorski, M. Yassine, 2008 .

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.

J. Abbruzzese, M. Rothenberg, T. Seay, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

M. Galsky, D. V. Von Hoff, M. Fleming, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary: do guidelines influence physician practice behavior? The experience with erythropoiesis-stimulating agents.

R. Beveridge, M. Neubauer, M. Kolodziej, 2009, Journal of oncology practice.

Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.

M. Neubauer, L. Asmar, S. Mull, 2006, Clinical genitourinary cancer.

Quality Improvement and Ethics: Performance Improvement in an Oncology Practice

M. Neubauer, John E Hennessy, 2002, The Journal of Clinical Ethics.

Disseminated Histoplasmosis in Patients With AIDS

M. Neubauer, D. Bodensteiner, 1992, Southern medical journal.

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network biomarker testing in metastatic NSCLC with first-line therapy.

N. Robert, R. Coleman, M. Karhade, 2022, Lung cancer.

Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer

J. Berlin, J. Hecht, H. Burris, 2010, Clinical Cancer Research.

Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.

M. Neubauer, L. Asmar, J. Olivares, 2004, Lung cancer.

Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial

David A. Smith, C. Obasaju, M. Socinski, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Cynthia S. Johnson, Constantin Yiannoutsos, Thomas Anderson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.

David A. Smith, M. Yassine, A. Cohn, 2011, Clinical colorectal cancer.

Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Edward S. Kim, S. Saxman, L. Schwartzberg, 2013, The Lancet. Oncology.

Successful treatment of primary adrenal insufficiency due to malignant non-Hodgkin's lymphoma

G. Krejs, G. Leb, H. Dobnig, 1992, The clinical investigator.

Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.

D. Bodkin, D. Richards, M. Neubauer, 2005, Clinical lung cancer.

Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer.

M. Socinski, M. Schell, D. Garfield, 2003, Lung cancer.

Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2‐neu Negative and Triple Negative Metastatic Breast Cancer

F. Holmes, J. O’Shaughnessy, M. Neubauer, 2017, Clinical breast cancer.

Prognostic factors in stage III non-small-cell lung cancer.

Cynthia S. Johnson, N. Hanna, F. Ademuyiwa, 2007, Clinical Lung Cancer.

Phase II Study of MGI‐114 Administered Intravenously for 5 Days Every 28 Days to Patients With Metastatic Colorectal Cancer

R. Winn, R. Pazdur, J. Abbruzzese, 2003, American journal of clinical oncology.

Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.

D. Patt, R. Beveridge, T. Cartwright, 2011, Journal of oncology practice.

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Lonny Reisman, R. Beveridge, S. Hoang, 2010, Journal of oncology practice.

Preliminary results of a phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2

M. Neubauer, L. Asmar, H. Ghaddar, 2004 .

Synchronous pulmonary carcinoid tumour and non-Hodgkin's lymphoma: report of two cases.

C. Fellbaum, H. Popper, M. Neubauer, 1989, Thorax.

Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system.

J. R. Hoverman, R. Harrell, Jad E Hayes, 2014, Journal of oncology practice.

Uncertainty from COVID-19 delays progress on the road to value-based cancer care.

M. Neubauer, Ben Jones, 2020, The American journal of managed care.

From angst to analytics : lessons learned from an oncology care model internal pilot

Stuart Staggs, J. Frytak, J. R. Hoverman, 2017 .

Benchmarks for value in cancer care: an analysis of a large commercial population.

D. Patt, R. Beveridge, B. Brooks, 2011, Journal of oncology practice.

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

M. Neubauer, L. Asmar, C. Reynolds, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

J. Gralow, J. O’Shaughnessy, J. Pippen, 2010, Clinical breast cancer.

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non–Small-Cell Lung Cancer in a Large Community Oncology Practice

P. Ward, D. Waterhouse, M. Neubauer, 2023, JCO oncology practice.

Impact of an oncology management program using level I pathways, a nurse call system, and advance care planning.

R. Harrell, Jad E Hayes, M. Neubauer, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)

N. Iannotti, N. Gabrail, A. Spira, 2007 .

Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status.

M. Yassine, A. Cohn, M. Neubauer, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Centers for Medicare & Medicaid Services Oncology Care Model Halfway Through - Perspectives from Diverse Participants.

J. Cox, L. Strawbridge, M. Neubauer, 2019, Journal of the National Cancer Institute.

Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy.

N. Hanna, R. Govindan, L. Einhorn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study

H. Lenz, S. Dakhil, J. Abbruzzese, 2006, Investigational New Drugs.

Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC)

M. Neubauer, L. Asmar, C. Reynolds, 2008 .

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

A. Das, N. Iannotti, N. Gabrail, 2012, Clinical lung cancer.

Mutation analysis and therapeutic response to granulocyte colony-stimulating factor in a case of hyperimmunoglobulin M syndrome with chronic neutropenia.

K. Kosuge, S. Nonoyama, M. Mori, 2000, Journal of pediatric hematology/oncology.

Improving incidence of code status documentation through process and discipline.

J. R. Hoverman, M. Neubauer, Cynthia B Taniguchi, 2015, Journal of oncology practice.

Creating a process to standardize regimen order sets within an electronic health record.

R. Beveridge, Roger T Anderson, M. Neubauer, 2011, Journal of oncology practice.